Product Images Divalproex Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Divalproex Sodium NDC 70518-3683 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
This is a medication called Divalproex Sodium. The tablet is delayed-release and has a strength of 125 mg. The quantity is 30 tablets and it is available only on prescription. The NDC number is 70518-3682-00 and the manufacturer is Rising Pharma, Inc. It is advised to keep this medication out of the reach of children and to see the package insert for directions of use. The medication should be stored between 20-25°C (88-77°F) with excursions permitted o 15-30°C (59-86°F) [See USP]. It has been repackaged by RemedyRepack Inc. in Indiana, PA.*
Figure 1 - divalproex fig1
The text describes a figure (Figure 1) that contains information about two studies, Study 1 and Study 2. The studies may relate to years and WIRS. The text also includes abbreviations, namely PBO, DVPX, and P80, which may have been used to represent various elements in the studies. Lastly, the text indicates that a statistical analysis was performed, and there was a significant difference between the placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) treatments, denoted by *p<0.05.*
Figure 2 - divalproex fig2
Figure 3 - divalproex fig3
The text is a chart showing the impact of dosage on the reduction of "InCPS Rate", with the x- axis labeled "High Dose" to "Low Dose" and the y-axis showing "% of Patients". The chart displays the percentage of patients with improvement, no change or worsening based on the dose.*
Figure 4 - divalproex fig4
The text describes the mean 4-week migraine rates for two studies involving the use of placebo and divalproex sodium delayed-release tablets. Study 1 had a mean dose of 1,087 mg/day while study 2 had a dose of either 500 or 1,000 mg/day of divalproex sodium delayed-release tablets.*
Chemical Structure - divalproex str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.